Shao Ning Yang

3.2k total citations
26 papers, 1.5k citations indexed

About

Shao Ning Yang is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Shao Ning Yang has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 10 papers in Pathology and Forensic Medicine and 8 papers in Immunology. Recurrent topics in Shao Ning Yang's work include Lymphoma Diagnosis and Treatment (8 papers), CAR-T cell therapy research (5 papers) and Epigenetics and DNA Methylation (4 papers). Shao Ning Yang is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), CAR-T cell therapy research (5 papers) and Epigenetics and DNA Methylation (4 papers). Shao Ning Yang collaborates with scholars based in United States, Canada and Argentina. Shao Ning Yang's co-authors include Leandro Cerchietti, Ari Melnick, Rita Shaknovich, José M. Polo, Katerina Hatzi, Karen Bunting, Olivier Elemento, Randy D. Gascoyne, Gabriela Chiosis and Amy Chadburn and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Nature Communications.

In The Last Decade

Shao Ning Yang

25 papers receiving 1.5k citations

Peers

Shao Ning Yang

ONCOL

IMMUN

PFM

GENET

Jonathan H. Schatz United States

Lukas P. Frenzel Germany

Lan V. Pham United States

Jingda Xu China

Mariana Nacht United States

Lixin Rui United States

Marc A. Weniger United States

Ingo Ringshausen Germany

Gerhard Niederfellner Germany

Michelle Kuhne United States

Jonathan H. Schatz United States

Shao Ning Yang

614 ×0.8

505 ×1.0

ONCOL

494 ×1.1

IMMUN

413 ×1.1

PFM

199 ×0.9

GENET

Citations per year, relative to Shao Ning Yang Shao Ning Yang (= 1×) peers Jonathan H. Schatz

Countries citing papers authored by Shao Ning Yang

Since Specialization

Citations

This map shows the geographic impact of Shao Ning Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shao Ning Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shao Ning Yang more than expected).

Fields of papers citing papers by Shao Ning Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shao Ning Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shao Ning Yang. The network helps show where Shao Ning Yang may publish in the future.

Co-authorship network of co-authors of Shao Ning Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Shao Ning Yang. A scholar is included among the top collaborators of Shao Ning Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shao Ning Yang. Shao Ning Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Han, Yoon-Chi, Luisa Shin Ogawa, Shao Ning Yang, et al.. (2023). Abstract 3415: Preclinical characterization of a brain penetrant RAF inhibitor, BDTX-4933, targeting oncogenic BRAF Class I/II/III and RAS mutations. Cancer Research. 83(7_Supplement). 3415–3415. 3 indexed citations

Ng, Pui Yee, Yoon-Chi Han, Luisa Shin Ogawa, et al.. (2022). Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations. European Journal of Cancer. 174. S86–S86. 1 indexed citations

Calvo-Vidal, M. Nieves, Nahuel Zamponi, Jan Krumsiek, et al.. (2021). Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. Cancer Research. 81(20). 5202–5216. 19 indexed citations

Dardenne, Étienne, Shao Ning Yang, Ahmet Mentes, et al.. (2021). 35MO Discovery and characterization of selective, FGFR1-sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers. Annals of Oncology. 32. S15–S15. 1 indexed citations

Dardenne, Étienne, Fernando Padilla, Shao Ning Yang, et al.. (2021). Abstract P246: Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers. Molecular Cancer Therapeutics. 20(12_Supplement). P246–P246. 1 indexed citations

Fernando, Tharu M., Rossella Marullo, Jude M. Phillip, et al.. (2019). BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. Cancer Discovery. 9(5). 662–679. 31 indexed citations

Marullo, Rossella, María V. Revuelta, Nahuel Zamponi, et al.. (2017). Exportin-1 Connects Dynamic Transcription and Translation of Genotoxic Stress Genes in Diffuse Large B-Cell Lymphoma Patients. Blood. 130. 312–312. 1 indexed citations

Cayrol, Florencia, Tharu M. Fernando, Nicholas Kwiatkowski, et al.. (2017). THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nature Communications. 8(1). 14290–14290. 71 indexed citations

Boi, Michela, Maria Chiara Todaro, Valentina Vurchio, et al.. (2016). Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget. 7(48). 79637–79653. 19 indexed citations

10.

Tian, Ye, Haelee Ahn, Rebecca Schneider, et al.. (2015). Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials. 73. 110–119. 65 indexed citations

11.

Patel, Jayeshkumar, Jan Krumsiek, Thibault Dupont, et al.. (2014). Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells. Blood. 124(21). 1764–1764. 1 indexed citations

12.

Cayrol, Florencia, María C. Díaz Flaqué, Tharu M. Fernando, et al.. (2014). Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood. 125(5). 841–851. 66 indexed citations

13.

Ruan, Jia, Min Luo, Chunjie Wang, et al.. (2013). Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 121(26). 5192–5202. 71 indexed citations

14.

Fontán, Lorena, Chenghua Yang, Venkataraman Kabaleeswaran, et al.. (2012). MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo. Cancer Cell. 22(6). 812–824. 202 indexed citations

15.

Cerchietti, Leandro, Christine Damm‐Welk, Inga Vater, et al.. (2011). Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas. PLoS ONE. 6(4). e18436–e18436. 39 indexed citations

16.

Shaknovich, Rita, Leandro Cerchietti, Lucas Tsikitas, et al.. (2011). DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 118(13). 3559–3569. 117 indexed citations

17.

Cerchietti, Leandro, Alexandru F. Ghetu, Xiao Zhu, et al.. (2010). A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo. Cancer Cell. 17(4). 400–411. 224 indexed citations

18.

Cerchietti, Leandro, Katerina Hatzi, Eloisi Caldas-Lopes, et al.. (2010). BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. Journal of Clinical Investigation. 120(12). 4569–4582. 87 indexed citations

19.

Cerchietti, Leandro, Eloisi Caldas Lopes, Shao Ning Yang, et al.. (2009). A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas. Nature Medicine. 15(12). 1369–1376. 132 indexed citations

20.

Ci, Weimin, José M. Polo, Leandro Cerchietti, et al.. (2009). The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 113(22). 5536–5548. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact